Japanese Medtech Giant Terumo Establishes $75M Venture Capital Fund

Terumo Corporation, a Japanese medical equipment manufacturer, has launched a new corporate venture capital (CVC) fund under the name “Terumo Ventures.” This initiative managed as a department within Terumo Americas Holding, Inc., will focus on driving the group’s venture investments.

The newly established fund will invest $75 million in healthcare technologies. Through these strategic investments, Terumo aims to explore potential mergers and acquisitions, further strengthening its position in the healthcare sector.

Terumo Ventures will operate in key global innovation hubs, including Massachusetts and California, as well as in the United States and Belgium. Over the next five years, the fund plans to invest in early-stage companies focused on cardiovascular disease treatment, chronic disease management, and digital technologies. This initiative aims to enhance Terumo’s access to breakthrough technologies and innovative business ideas from startups, supporting open innovation and synergy with its internal R&D efforts.

Since 2013, Terumo has been cultivating relationships with medtech startups by investing in venture capital funds in the U.S. and China. The establishment of Terumo Ventures will allow the company to be more agile in identifying and executing venture investments, accelerating its ability to acquire technologies and develop a strong pipeline for future mergers and acquisitions.

Terumo has included the launch of this CVC in its 5-Year Growth Strategy, “GS26,” and its long-term vision of transitioning “From Devices to Solutions.” By focusing on solutions to address various medical challenges and unmet needs, Terumo aims to expand its foothold in the healthcare industry.

Additionally, Terumo has introduced a new director position dedicated to overseeing innovation-related functions across the company. Established in April 2024, this role is responsible for centrally managing areas such as research and development, intellectual property, clinical development, digital transformation, and venture investments. The goal is to facilitate cross-functional collaboration and streamline the company’s innovation processes.

Terumo plans to expand its innovation capabilities through a combination of internal development and strategic partnerships with external entities. This approach will enable the company to continue providing valuable medical solutions and address evolving healthcare needs, ultimately benefiting patients, medical professionals, and society as a whole.

With a century-long legacy in the medical technology industry, Terumo remains dedicated to its mission of “Contributing to Society through Healthcare.” Headquartered in Tokyo, the company operates globally with over 30,000 employees and offers a wide range of medical products and services in over 160 countries. From vascular interventions and cardio-surgical solutions to blood transfusion systems and diabetes care, Terumo continues to be a key player in advancing healthcare worldwide.

Also Read:

• Thailand’s BOI Launches Matching Fund to Support High-Potential Startups
• Yuno’s $25M Push into Asia: Jonathan Hall Discusses Growth and Challenges
• Beep Expands Voltality Network Across Southeast Asia with $3.3M Funding Boost
• Khazanah Nasional Completes Acquisition of MAVCAP and Penjana Kapital, Launches RM1 Billion National Fund-of-Funds
• Innovation Exchange Program Recap: Insights from Kishore Ravichandran on Startup-Corporate Collaboration